Document Type

Journal Article

Publication Date

4-1-2014

Journal

Diabetes Care

Volume

37

Issue

4

Inclusive Pages

909-911

DOI

10.2337/dc13-0700

Keywords

Diabetes Mellitus, Type 2--epidemiology; Diabetes Mellitus, Type 2--genetics; Diabetes, Gestational--drug therapy; Diabetes, Gestational--epidemiology; Hypoglycemic Agents--therapeutic use; Life Style; Metformin--therapeutic use; Prediabetic State--drug therapy; Prediabetic State--epidemiology

Abstract

OBJECTIVE The Diabetes Prevention Program (DPP) trial investigated rates of progression to diabetes among adults with prediabetes randomized to treatment with placebo, metformin, or intensive lifestyle intervention. Among women in the DPP, diabetes risk reduction with metformin was greater in women with prior gestational diabetes mellitus (GDM) compared with women without GDM but with one or more previous live births.

RESEARCH DESIGN AND METHODS We asked if genetic variability could account for these differences by comparing β-cell function and genetic risk scores (GRS), calculated from 34 diabetes-associated loci, between women with and without histories of GDM.

RESULTS β-Cell function was reduced in women with GDM. The GRS was positively associated with a history of GDM; however, the GRS did not predict progression to diabetes or modulate response to intervention.

CONCLUSIONS These data suggest that a diabetes-associated GRS is associated with development of GDM and may characterize women at risk for development of diabetes due to β-cell dysfunction.

Comments

Reproduced with permission of the American Diabetes Association. Diabetes Care

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.

Peer Reviewed

1

Open Access

1

Download

Share

COinS